Co-existing infantile hepatic hemangioma and mesenchymal hamartoma in a neonate

Nicolas Berte1, Alya Filfilan1, Laurence Mainard2

  • 1Department of Pediatric Surgery, CHRU Nancy, 54500 Vandoeuvre-lès-Nancy, France.

Insights

This case report details a newborn with infantile hepatic hemangioma (IHH) and mesenchymal hamartoma (MH), experiencing severe complications. Successful treatment involved surgery and beta-blockers, leading to a full recovery.

Area of Science:

  • Pediatric Oncology
  • Hepatology
  • Surgical Pathology

Background:

  • Infantile hepatic hemangioma (IHH) and mesenchymal hamartoma (MH) are the most common pediatric liver tumors.
  • Early diagnosis and management are crucial for favorable outcomes in affected newborns.

Observation:

  • A newborn presented with a rapidly growing liver mass, anemia, respiratory, and renal failure.
  • Imaging revealed multifocal cystic and solid liver lesions with arterial enhancement.
  • Elevated alpha-fetoprotein levels were noted in the absence of cardiac or cutaneous signs.

Findings:

  • Pathological analysis confirmed synchronous IHH (GLUT-1 positive) and MH.
  • Initial non-anatomical liver resection was followed by further surgical interventions for persistent lesions.
  • Combined surgical and medical treatment (beta-blockers) led to lesion resolution.

Implications:

  • This case highlights the importance of prompt diagnosis and multidisciplinary management for complex pediatric liver tumors.
  • The successful use of beta-blockers suggests a potential role in managing refractory or complex cases of IHH and MH.
  • Synchronous occurrence of IHH and MH, though rare, requires careful consideration in the differential diagnosis of neonatal liver masses.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.4K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
255
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.7K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
626
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
313